Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2002-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12479217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human breast cancer cell lines as models of growth regulation and disease progression

  2005cited by this paper
• Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells

  2004cited by this paper
• Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.

  2002influential reference
• Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.

  2001cited by this paper
• Differential Localization of Rho Gtpases in Live Cells

  2001cited by this paper
• Small GTP-binding proteins.

  2001cited by this paper
• In vivo prenylation analysis of Ras and Rho proteins.

  2001cited by this paper
• RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors

  2000cited by this paper
• Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics.

  2000cited by this paper
• Rho-like GTPases in tumor cell invasion.

  2000cited by this paper
• Genomic analysis of metastasis reveals an essential role for RhoC

  2000cited by this paper
• Untying the Gordian Knot of Cytokinesis: Role of Small G Proteins and Their Regulators

  2000cited by this paper
• RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

  2000cited by this paper
• The specific binding of small molecule isoprenoids to rhoGDP dissociation inhibitor (rhoGDI).

  2000cited by this paper
• Untying the Gordian Knot of Cytokinesis

  2000cited by this paper
• Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.

  2000cited by this paper
• Oncogenic Ras Downregulates Rac Activity, Which Leads to Increased Rho Activity and Epithelial–Mesenchymal Transition

  2000cited by this paper
• Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants

  2000cited by this paper
• RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

  2000influential reference
• Rho GTPases and their effector proteins.

  2000cited by this paper
• Recent advances in the study of prenylated proteins.

  2000cited by this paper
• Geranylgeranylated RhoB is sufficient to mediate tissue‐specific suppression of Akt kinase activity by farnesyltransferase inhibitors

  2000cited by this paper
• Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

  2000cited by this paper
• Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

  1999cited by this paper
• A Built-in Arginine Finger Triggers the Self-stimulatory GTPase-activating Activity of Rho Family GTPases*

  1999cited by this paper
• Effectors for the Rho GTPases.

  1999cited by this paper
• Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB

  1999cited by this paper
• A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype.

  1999cited by this paper
• Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.

  1999influential reference
• Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling.

  1999influential reference
• GTPase-activating proteins and their complexes.

  1998cited by this paper
• Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway

  1998cited by this paper
• Negative Regulation of Rho Family GTPases Cdc42 and Rac2 by Homodimer Formation*

  1998cited by this paper
• Membrane association and targeting of prenylated Ras-like GTPases.

  1998cited by this paper
• Non-Ras targets of farnesyltransferase inhibitors: focus on Rho

  1998cited by this paper
• Rho family proteins and Ras transformation: the RHOad less traveled gets congested

  1998cited by this paper
• Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.

  1998cited by this paper
• The GTP-binding protein Rho.

  1997cited by this paper
• Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis).

  1997cited by this paper
• Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB*

  1997cited by this paper
• Protein Prenylation, et cetera--Signal Transduction in Two Dimensions

  1997cited by this paper
• Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.

  1997cited by this paper
• GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins.

  1997cited by this paper
• Linear Mixed Models in Practice: A SAS-Oriented Approach

  1997cited by this paper
• Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones

  1996cited by this paper
• The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton

  1996cited by this paper
• Chemical biology of protein isoprenylation/methylation.

  1996cited by this paper
• erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.

  1996cited by this paper
• Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

  1995cited by this paper
• Regulation of Ras-related RhoB protein expression during the cell cycle.

  1995cited by this paper
• Critical role of Rho in cell transformation by oncogenic Ras.

  1995cited by this paper
• Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia.

  1995cited by this paper
• Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

  1994cited by this paper
• Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes.

  1994cited by this paper
• Small GTP-binding proteins and the regulation of the actin cytoskeleton.

  1994cited by this paper
• Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.

  1993cited by this paper
• Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

  1993cited by this paper
• Peptidomimetic inhibitors of Ras farnesylation and function in whole cells.

  1993cited by this paper
• Inflammatory breast cancer: a review.

  1992cited by this paper
• Small GTP-binding proteins.

  1992cited by this paper
• Post-translational modifications of p21rho proteins.

  1992cited by this paper
• A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.

  1991cited by this paper
• The gamma subunit of transducin is farnesylated.

  1990cited by this paper
• Suppression of programmed death and G1 arrest in B‐cell hybridomas by interleukin‐6 is not accompanied by altered expression of immediate early response genes

  1990cited by this paper
• Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements.

  1990cited by this paper
• All ras proteins are polyisoprenylated but only some are palmitoylated.

  1989cited by this paper
• The phagokinetic tracks of 3T3 cells.

  1977cited by this paper
• The manual for the staging of cancer.

  1977cited by this paper
• AGAR SUSPENSION CULTURE FOR THE SELECTIVE ASSAY OF CELLS TRANSFORMED BY POLYOMA VIRUS.

  1964cited by this paper

• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells

  2025cites this paper
• Targeting Signaling Pathways in Inflammatory Breast Cancer

  2020cites this paper
• Rho GTPases: Big Players in Breast Cancer Initiation, Metastasis and Therapeutic Responses

  2020cites this paper
• Inflammatory Breast Cancer: a Separate Entity

  2019cites this paper
• Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network.

  2019cites this paper
• The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells

  2019cites this paper
• Targeting the actin polymerisation pathway for improved treatment of glioblastoma

  2019cites this paper
• Inflammatory Breast Cancer: Diagnostic, Molecular and Therapeutic Considerations

  2019cites this paper
• In vitro vascularized tumor platform for modeling tumor‐vasculature interactions of inflammatory breast cancer

  2018cites this paper
• In vitro vascularized tumor platform for modeling breast tumor stromal interactions and characterizing the subsequent response

  2018cites this paper
• Specific role of RhoC in tumor invasion and metastasis

  2017cites this paper
• Paving the Rho in cancer metastasis: Rho GTPases and beyond.

  2017cites this paper
• Analysis of Integrin Alpha 2 Beta 1 (α 2 β 1 ) Expression as a Biomarker of Skeletal Metastasis

  2017cites this paper
• The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer

  2016cites this paper
• Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner

  2016cites this paper
• Developmental therapeutics for inflammatory breast cancer: Biology and translational directions

  2016cites this paper
• Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials

  2014cites this paper
• Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration

  2014cites this paper
• How Do I Treat Inflammatory Breast Cancer?

  2013cites this paper
• Modeling and characterization of inflammatory breast cancer emboli grown in vitro

  2013cites this paper
• Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.

  2013cites this paper
• Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review

  2013influential citation
• Inflammatory breast cancer: New factors contribute to disease etiology: A review

  2013cites this paper
• Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

  2013cites this paper
• The Molecular Biology of Inflammatory Breast Cancer

  2013cites this paper
• Inflammatory Breast Cancer Stem Cells: Contributors to Aggressiveness, Metastatic Spread and Dormancy

  2012cites this paper
• Molecules That Drive the Invasion and Metastasis of Inflammatory Breast Cancer

  2012cites this paper
• Signaling Pathways in Inflammatory Breast Cancer

  2012cites this paper
• RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA

  2012cites this paper
• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

  2012cites this paper
• IGF-1 Cellular Action and its Relationship to Cancer: Evidence from in Vitro and in Vivo Studies

  2012cites this paper
• Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer

  2012cites this paper
• Inflammatory Breast Cancer: An Update

  2012cites this paper
• Amphiregulin (AREG) and epidermal growth factor (EGF): Disparate in EGFR signaling and trafficking

  2011cites this paper
• High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes

  2011cites this paper
• Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype

  2011cites this paper
• Insight into the 6-thiopurine-mediated termination of the invasive motility of tumor cells derived from inflammatory breast cancer.

  2011cites this paper
• Breast Cancer Stem Cells Survive Periods of Farnesyl-Transferase Inhibitor-Induced Dormancy by Undergoing Autophagy

  2011cites this paper
• Inflammatory breast cancer: novel preoperative therapies.

  2010cites this paper
• Inhibition of GGTase‐I and FTase disrupts cytoskeletal organization of human PC‐3 prostate cancer cells

  2010cites this paper
• Gene expression profiling of inflammatory breast cancer

  2010cites this paper
• RhoC GTPase activation assay.

  2010cites this paper
• Rho GTPases in Regulation of Cancer Cell Motility, Invasion, and Microenvironment

  2010cites this paper
• Mechanism of Metastasis to Bone: The Role of Bone Marrow Endothelium

  2010cites this paper
• Inflammatory Breast Cancer: The Disease, the Biology, the Treatment

  2010cites this paper
• Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

  2010cites this paper
• RhoB GTPase and FTIs in Cancer

  2010cites this paper
• The Role of Integrins in Enterovirus Infections and in Metastasis of Cancer

  2010cites this paper
• RhoC GTPase in Cancer Progression and Metastasis

  2010cites this paper
• Bisphosphonate Inhibition of Prostate Cancer Cell Invasion, Migration and Cytoskeletal Organization

  2010cites this paper
• RhoC in melanoma: possible target for statin treatment

  2010cites this paper
• Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-CyclophosphamideinPatientswithClinicalStage IIB-IIIC BreastCancer

  2009cites this paper
• Delayed rejection of MHC class II-disparate skin allografts in mice treated with farnesyltransferase inhibitors.

  2009cites this paper
• Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer

  2009cites this paper
• The role of RhoC in growth and metastatic capacity of melanoma

  2009cites this paper
• RhoA, B, and C in cancer: Study of statin-induced changes in Rho signaling, and identification of isoform-specific Rho effectors

  2009cites this paper
• Charakterisierung der Rekrutierungsdomäne der kleinen Rho-GTPasen RhoA und RhoC

  2009cites this paper
• Molecular targets for treatment of inflammatory breast cancer

  2009cites this paper
• Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

  2008cites this paper
• Biology of Inflammatory Breast Cancer

  2008cites this paper
• Interactions et coopérations cellulaires dans le processus métastatique

  2008cites this paper
• Molecular determinants of the inflammatory breast cancer phenotype.

  2008cites this paper
• Genetic determinants of aggressive breast cancer.

  2008cites this paper
• Type I collagen receptor (α2β1) signaling promotes prostate cancer invasion through RhoC GTPase

  2008cites this paper
• Defining the molecular biology of inflammatory breast cancer.

  2008cites this paper
• The predictive value of PgR and HER-2 for response to primary systemic chemotherapy in inflammatory breast cancer

  2008cites this paper
• Role of Rho GTPases in breast cancer.

  2008cites this paper
• mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition

  2007cites this paper
• RhoA and RhoC -siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway.

  2007cites this paper
• Implication des voies de signalisation de l'adhérence cellulaire dans le contrôle de l'hypoxie tumorale des glioblastomes

  2007cites this paper
• Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma

  2007cites this paper
• ROCK I-mediated activation of NF-κB by RhoB

  2007cites this paper
• ROCK I-mediated activation of NF-kappaB by RhoB.

  2007cites this paper
• The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.

  2006cites this paper
• Award Number : DAMD 17-02-1-0490 TITLE : Detection of Metastatic Potential in Breast Cancer by RhoC-GTPase and WISP 3 Proteins

  2006cites this paper
• ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells.

  2006cites this paper
• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

  2006cites this paper
• Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone.

  2006cites this paper
• Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

  2006cites this paper
• Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

  2006influential citation
• Molecular Biology of Inflammatory Breast Cancer: Applications to Diagnosis, Prognosis, and Therapy

  2006cites this paper
• Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.

  2006cites this paper
• Type I Collagen Receptor (α2β1) Signaling Promotes the Growth of Human Prostate Cancer Cells within the Bone

  2006cites this paper
• THE ACTIN CYTOSKELETON AND METASTASIS

  2006cites this paper
• Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms,and Progress in the Clinic

  2006cites this paper
• Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.

  2005cites this paper
• Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection.

  2005cites this paper
• RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast

  2005cites this paper
• Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion

  2005cites this paper
• In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line

  2005cites this paper
• In Vivo Fluorescence Confocal Microscopy to Investigate the Role of RhoC in Inflammatory Breast Cancer

  2005cites this paper
• Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update

  2004cites this paper
• The Tension Mounts: Mechanics Meets Morphogenesis and Malignancy

  2004cites this paper
• Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway.

  2004cites this paper
• Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?

  2004cites this paper
• Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy

  2004cites this paper
• A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice

  2004cites this paper
• Novel Agents for the Prevention of Breast Cancer: Targeting Transcription Factors and Signal Transduction Pathways

  2004cites this paper
• The Mevalonate Synthesis Pathway as a Therapeutic Target in Cancer

  2003cites this paper